cas 922-67-8|| where to buy methyl prop-2-ynoate

Nom du produit:methyl prop-2-ynoate

IUPAC Name:methyl prop-2-ynoate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM326338-250g	in stock	řǎŁ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 922-67-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:922-67-8; Formule moléculaire:C4H4O2; Point de fusion:-; Code SMILES:C#CC(OC)=O; Densité:

: Numéro de catalogue:CM326338; Poids moléculaire:84.07; Point d'ébullition:104°C at 760 mmHg; N° Mdl:MFCD00008572; Stockage:Inert atmosphere,2-8°C

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Brensocatib; May 28 2024, Insmed announced positive topline results from landmark ASPEN study of Brensocatib in patients with bronchiectasis.
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed for the treatment of patients with bronchiectasis, CRSsNP, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.